newsfilter
← Latest News
GlobeNewswire·

Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering

ETRA
  • Electra Therapeutics priced an upsized initial public offering of 23,333,334 common stock shares at $15.00 per share.
  • Gross proceeds from the offering are expected to be approximately $350.0 million before deducting underwriting discounts, commissions, and estimated expenses.
  • Underwriters have been granted a 30-day option to purchase up to an additional 3,500,000 shares at the public offering price less discounts.
  • Shares are scheduled to begin trading on The Nasdaq Global Select Market on September 18, 2026, under the ticker symbol "ETRA."
  • The offering is expected to close on September 21, 2026, subject to customary closing conditions.
  • Jefferies, TD Cowen, Evercore ISI, and Cantor are acting as joint book-running managers.
  • Electra Therapeutics is a late clinical-stage biopharmaceutical company developing precision medicines targeting signal regulatory proteins (SIRP) for immune-mediated diseases and cancer.
  • The company's lead candidate, ipsoprubart (ELA026), is in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH) and a Phase 1 trial for T-cell and natural-killer cell malignancies.
  • The second clinical-stage candidate, ELA822, is a SIRPγ-specific antibody being developed for chronic T cell-mediated immune and inflammatory diseases.
  • Registration statements became effective on September 17, 2026, with copies available via the SEC website.